BioCentury | Jan 29, 2020
Product Development

Decibel narrows discovery focus to inner ear regeneration, taps Reid as CEO

Under the leadership of incoming CEO Laurence Reid, hearing loss company Decibel is starting its next chapter in drug discovery with a narrowed focus on inner ear cell regeneration and programs in balance disorders. Reid...
BioCentury | Jul 3, 2019
Emerging Company Profile

Kymera: a systematic approach to protein degradation

With a computational drug discovery platform and a proprietary library of E3 ligases and binders, Kymera believes it can accelerate the discovery and development of protein degraders. Protein degradation is entering the mainstream as a...
BC Innovations | Jun 4, 2019
Distillery Techniques

Tool compounds for probing the role of human cGAS in inflammatory diseases

TECHNIQUES CATEGORY: Chemistry TECHNOLOGY: Tool compound Small molecule inhibitors of human cGAS could be used to probe the role of cGAS-dependent signaling in inflammatory diseases. Screening of a compound library followed by optimization of the...
BC Extra | May 22, 2019
Politics & Policy

Launch of germline gene editing commission provides first look at priorities, representatives

An international commission tasked with creating a framework for assessing potential clinical applications of human germline genome editing launched Wednesday, providing the first details of the composition of its membership and oversight board, timeline and...
BC Innovations | Mar 7, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: February 2019

New Therapeutic Targets and Biomarkers: February 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during February. Therapeutic targets are defined as any protein, gene or other molecule...
BC Innovations | Feb 13, 2019
Distillery Therapeutics

Infectious disease

INDICATION: Infectious In vitro and mosquito studies identified a quinazoline-based agonist of A. aegypti NPYLR7 that could help prevent A. aegypti mosquito bites and associated infections. In vitro screening of a compound library in agonistic...
BioCentury | Feb 8, 2019
Emerging Company Profile

Palleon: Sweeter checkpoints

With two platforms targeting glycan ligands and their receptors, and a third to match cancer patients to a therapy, Palleon Pharmaceuticals Inc. aims to treat cancer by removing the brakes on a class of checkpoints...
BC Week In Review | Jan 18, 2019
Company News

Bioharmony, Boehringer partner to develop antimicrobials

Antimicrobial company Bioharmony Therapeutics Inc. (New York, N.Y.) partnered with Boehringer Ingelheim GmbH (Ingelheim, Germany) to develop bacteriophage lysins to treat systemic multidrug-resistant Acinetobacter infections. Bioharmony declined to disclose financial terms and details regarding the...
BC Extra | Jan 15, 2019
Company News

Bioharmony, Boehringer partner to develop antimicrobials

Antimicrobial company Bioharmony Therapeutics Inc. (New York, N.Y.) partnered with Boehringer Ingelheim GmbH (Ingelheim, Germany) to develop bacteriophage lysins to treat systemic multidrug-resistant Acinetobacter infections. Bioharmony declined to disclose financial terms and details regarding the...
BC Week In Review | Jan 11, 2019
Clinical News

Contrafect to test S. aureus therapy in Phase III despite Phase II miss

Exebacase (CF-301) from ContraFect Corp. (NASDAQ:CFRX) plus standard of care (SOC) antibiotics missed the primary endpoint of improving clinical response rate at day 14 vs. SOC alone in a Phase II trial to treat Staphylococcus...
Items per page:
1 - 10 of 315
BioCentury | Jan 29, 2020
Product Development

Decibel narrows discovery focus to inner ear regeneration, taps Reid as CEO

Under the leadership of incoming CEO Laurence Reid, hearing loss company Decibel is starting its next chapter in drug discovery with a narrowed focus on inner ear cell regeneration and programs in balance disorders. Reid...
BioCentury | Jul 3, 2019
Emerging Company Profile

Kymera: a systematic approach to protein degradation

With a computational drug discovery platform and a proprietary library of E3 ligases and binders, Kymera believes it can accelerate the discovery and development of protein degraders. Protein degradation is entering the mainstream as a...
BC Innovations | Jun 4, 2019
Distillery Techniques

Tool compounds for probing the role of human cGAS in inflammatory diseases

TECHNIQUES CATEGORY: Chemistry TECHNOLOGY: Tool compound Small molecule inhibitors of human cGAS could be used to probe the role of cGAS-dependent signaling in inflammatory diseases. Screening of a compound library followed by optimization of the...
BC Extra | May 22, 2019
Politics & Policy

Launch of germline gene editing commission provides first look at priorities, representatives

An international commission tasked with creating a framework for assessing potential clinical applications of human germline genome editing launched Wednesday, providing the first details of the composition of its membership and oversight board, timeline and...
BC Innovations | Mar 7, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: February 2019

New Therapeutic Targets and Biomarkers: February 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during February. Therapeutic targets are defined as any protein, gene or other molecule...
BC Innovations | Feb 13, 2019
Distillery Therapeutics

Infectious disease

INDICATION: Infectious In vitro and mosquito studies identified a quinazoline-based agonist of A. aegypti NPYLR7 that could help prevent A. aegypti mosquito bites and associated infections. In vitro screening of a compound library in agonistic...
BioCentury | Feb 8, 2019
Emerging Company Profile

Palleon: Sweeter checkpoints

With two platforms targeting glycan ligands and their receptors, and a third to match cancer patients to a therapy, Palleon Pharmaceuticals Inc. aims to treat cancer by removing the brakes on a class of checkpoints...
BC Week In Review | Jan 18, 2019
Company News

Bioharmony, Boehringer partner to develop antimicrobials

Antimicrobial company Bioharmony Therapeutics Inc. (New York, N.Y.) partnered with Boehringer Ingelheim GmbH (Ingelheim, Germany) to develop bacteriophage lysins to treat systemic multidrug-resistant Acinetobacter infections. Bioharmony declined to disclose financial terms and details regarding the...
BC Extra | Jan 15, 2019
Company News

Bioharmony, Boehringer partner to develop antimicrobials

Antimicrobial company Bioharmony Therapeutics Inc. (New York, N.Y.) partnered with Boehringer Ingelheim GmbH (Ingelheim, Germany) to develop bacteriophage lysins to treat systemic multidrug-resistant Acinetobacter infections. Bioharmony declined to disclose financial terms and details regarding the...
BC Week In Review | Jan 11, 2019
Clinical News

Contrafect to test S. aureus therapy in Phase III despite Phase II miss

Exebacase (CF-301) from ContraFect Corp. (NASDAQ:CFRX) plus standard of care (SOC) antibiotics missed the primary endpoint of improving clinical response rate at day 14 vs. SOC alone in a Phase II trial to treat Staphylococcus...
Items per page:
1 - 10 of 315